Clinical Trial Update: Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

Pfizer completed a Phase 3 trial evaluating varenicline (Chantix) for smoking cessation in patients with schizophrenia or schizoaffective disorder; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• CHANTIX (varenicline tartrate)

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED | Results posted: 2011-04-15